A Randomized, Open-label, Active-controlled, 3-arm Parallel-group, 26-week Study Comparing the Efficacy and Safety of Lixisenatide to That of Insulin Glulisine Once Daily and Insulin Glulisine Three Times Daily in Patients With Type 2 Diabetes Insufficiently Controlled With Insulin Glargine With or Without Metformin
Latest Information Update: 30 Jan 2023
At a glance
- Drugs Lixisenatide (Primary) ; Insulin glulisine
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms GetGoal-Duo-2
- Sponsors Sanofi
- 05 Oct 2018 Results of a propensity score-matched analysis to Compare LixiLan-L and GetGoal Duo-2 trials presented at the 54th Annual Meeting of the European Association for the Study of Diabetes
- 15 Sep 2017 Results of exploratory analysis assessing if iGlarLixi is more effective and better tolerated than sequential injections of iGlar and Lixi using patient data from NCT02058160 and NCT01768559 trials presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes
- 13 Jun 2017 Results of a propensity score-matched analysis to Compare LixiLan-L and GetGoal Duo-2 trials presented at the 77th Annual Scientific Sessions of the American Diabetes Association